Sarepta Therapeutics

New 'Voice of the Patient' Report Highlights Unmet Medical Needs of Six Subtypes of Limb-Girdle Muscular Dystrophy

Retrieved on: 
Monday, May 15, 2023
Prescription Drug User Fee Act, Partnership, Muscular dystrophy, University, ML, Research, Patient, Common, Human voice, Sarepta Therapeutics, LGMD, PDUFA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Caregiver, Pharmaceutical industry

This meeting focused on LGMD subtypes LGMD2A/R1, LGMD2C/R5, LGMD2D/R3, LGMD2E/R4, LGMD2F/R6, and LGMD2i/R9.

Key Points: 
  • This meeting focused on LGMD subtypes LGMD2A/R1, LGMD2C/R5, LGMD2D/R3, LGMD2E/R4, LGMD2F/R6, and LGMD2i/R9.
  • An additional 136 patients and family members responded to a live survey and over 250 written comments were submitted.
  • The LGMD Coalition is appreciative for support from our sponsors, Sarepta Therapeutics, AskBio, Edgewise Therapeutics, ML BioSolutions, and Vita Therapeutics.
  • We believe that their engagement in this process provided insights into these subtypes of LGMD which will help the research community develop effective therapies."

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 28, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, SRPT, Sarepta, Sarepta Therapeutics, Employment, Rare, Therapy, RSU, Compensated emancipation

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 18 individuals hired by Sarepta in April 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 18 individuals hired by Sarepta in April 2023.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 9,975 shares of Sarepta's common stock, and in the aggregate 5,125 restricted stock units (“RSUs”).
  • The options have an exercise price of $122.77 per share, which is equal to the closing price of Sarepta's common stock on April 28, 2023 (the “Grant Date”).

Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 18, 2023
Fox News, Defamation, P.C, FOX, Sarepta Therapeutics, May 29, Fox, Bank statement, DOJ, SRPT, Sarepta, Trump, Smartmatic, Research, OTP, FOXA, Provident, Primate, CRL, BLA, News, NYSE, Murdoch family, Food, Delaware Superior Court, Dominion Voting Systems, Fox Corporation, Pharmaceutical industry, Audit, Cryptocurrency, Dominion, Therapy

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • In November and December of 2020, Fox News broadcasted reports stating that the U.S. election was rigged.
  • Fox News specifically called out Smartmatic and Dominion Voting Systems, voting technology and software companies, for their alleged involvement in rigging the election.
  • On this news, shares of Charles River fell by as much as 15% in intraday trading on the same day.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

Retrieved on: 
Monday, April 17, 2023
Titan, Sarepta Therapeutics, Food and Drug Administration, BBC World Service, SRPT, Sarepta, Plaintiff, Investor's Business Daily, OTP, Risk, Advertising, UBS, Regulation of tobacco by the U.S. Food and Drug Administration, BLA, News, I-Space (Chinese company), Food, May 29, Cryptocurrency, Therapy

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=1306 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

Retrieved on: 
Sunday, April 16, 2023
Titan, Sarepta Therapeutics, Food and Drug Administration, BBC World Service, SRPT, Sarepta, Plaintiff, Investor's Business Daily, OTP, Risk, Advertising, UBS, Regulation of tobacco by the U.S. Food and Drug Administration, BLA, News, I-Space (Chinese company), Food, May 29, Cryptocurrency, Therapy

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Sarepta Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Saturday, April 15, 2023
SRPT, Sarepta Therapeutics, FDA, News, May 29, Cryptocurrency, Pharmaceutical industry, Therapy

LOS ANGELES, April 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Sarepta investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, April 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors.
  • Sarepta investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Ongoing Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Retrieved on: 
Friday, April 14, 2023
Dystrophin, Sarepta Therapeutics, SRPT, Website, RNA, OTP, SAN, Rare, BLA, News, Food, May 29, Pharmaceutical industry, Medical device, Therapy

SAN DIEGO, April 14, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces its ongoing investigation into potential violations of U.S. federal securities laws by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) focused on whether Sarepta and certain of its top executive officers made false and misleading statements and/or failed to disclose material information to investors.

Key Points: 
  • SAN DIEGO, April 14, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces its ongoing investigation into potential violations of U.S. federal securities laws by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) focused on whether Sarepta and certain of its top executive officers made false and misleading statements and/or failed to disclose material information to investors.
  • If you have information that could assist in this investigation or if you are a Sarepta investor who suffered a loss and would like to learn more, you can provide your information here:
    You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] .
  • THE COMPANY: Sarepta is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
  • Sarepta is developing SRP-9001 (delandistrogene moxeparvovec), an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of functional components of dystrophin.

Investigation of Sarepta Therapeutics, Inc. (SRPT) Announced by Holzer & Holzer, LLC

Retrieved on: 
Friday, April 14, 2023
SRPT, Sarepta Therapeutics, Fraud, OTP, BLA, Food, May 29, ISS, Pharmaceutical industry, Therapy

ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) complied with federal securities laws.

Key Points: 
  • ATLANTA, April 14, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) complied with federal securities laws.
  • If you purchased Sarepta Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Marshall Dees, Esq.
  • Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

SRPT INVESTOR NEWS: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

Retrieved on: 
Saturday, April 15, 2023
Titan, Sarepta Therapeutics, SRPT, Sarepta, OTP, Risk, Advertising, UBS, BLA, News, I-Space (Chinese company), Food, May 29, Cryptocurrency, Therapy

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=1306 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

Retrieved on: 
Sunday, April 9, 2023
Titan, Sarepta Therapeutics, SRPT, Sarepta, OTP, Risk, Advertising, UBS, BLA, News, I-Space (Chinese company), Food, May 29, Cryptocurrency, Therapy

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=1306 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.